Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
Afatinib is an irreversible epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is known to be effective against the EGFR T790M variant, which accounts for half of the mechanisms of acquired resistance to reversible EGFR-TKIs. However, acquired resistance to afatinib was als...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638008/ |